Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Manufacturing

Set Alert for Manufacturing

Billionaire Mark Cuban Surprises With US Generics Venture

 To increase transparency and affordability, American billionaire and businessman Mark Cuban has launched a US generics venture under the name ‘the Mark Cuban Cost Plus Drugs Company.’ Cuban’s new company is hoping to introduce over 100 drugs by the end of 2021 and build a pharmaceutical factory of its own by 2022. 

Generic Drugs Manufacturing

Hikma Stands Firm On Supply As It Scoffs At Latest Amarin Lawsuit

Hikma addressed supply concerns and the latest legal worries for its generic Vascepa product, as well as the recent launch of its long-awaited Advair generic, as management faced the virtual J.P. Morgan Healthcare Conference.

Generic Drugs Strategy

Sanofi Reveals Details Of European API Business

Sanofi has unveiled further details of its European API company, which will be called Euroapi and will be led by Karl Rotthier as CEO.

Manufacturing Ingredients

Amarin Raises Supply Issue Again On US Vascepa Generics

With Hikma having launched the first generic version of Vascepa (icosapent ethyl) in the US last year, Amarin has again raised the issue of ANDA product supply for the complex purified fish oil brand.

Generic Drugs Manufacturing

Siegfried Achieves Desired Scale After Completing Novartis Plant Deal

Siegfried has completed the acquisition of two Spanish manufacturing facilities from Novartis, in a move that will significantly enhance the Swiss CDMO’s capacity.

Deals Manufacturing

Alvotech’s Iceland Expansion Will Double Capacity

As Alvotech advances towards launches around the world for its portfolio of biosimilars, the firm is ramping up capacity at its Reykjavik facility.

Manufacturing Biosimilars
See All
UsernamePublicRestriction

Register